-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansoh Pharma reports 81.5% response rate in Phase Ib HS-10370 combo trial in first-line KRAS G12C NSCLC

PUBT·09/14/2026 08:48:22
Listen to the news
Hansoh Pharma reports 81.5% response rate in Phase Ib HS-10370 combo trial in first-line KRAS G12C NSCLC
  • Hansoh Pharma disclosed Phase Ib results at WCLC 2026 for HS-10370 with adebrelimab and platinum chemotherapy in untreated KRAS G12C-mutated advanced NSCLC.
  • The regimen produced strong tumor shrinkage signals in first-line patients, with responses seen across PD-L1 expression subgroups.
  • Safety appeared manageable, with side effects broadly consistent with the known profiles of the medicines in the combination.
  • The readout supports moving the combination into a Phase 3 trial, positioning HS-10370 for a potential first-line targeted market opportunity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.